Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, re...
Jefferies analyst Peter Welford maintains Novartis (NYSE:NVS) with a Buy and raises the price target from $121 to $122.5.
A Mississippi judge upheld a state law requiring drugmakers to offer discounts on medications through third-party pharmacies fo...
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addr...
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.
Trevena shares dropped 33.7% to $0.23 with a session volume of 23.65 million. Notably, TRV045 did not cause S1P1R desensitizati...
-Reuters
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market l...
Novartis has filed a lawsuit to block a Maryland law requiring drugmakers to offer discounts on drugs through third-party pharm...
